FDA issued a letter to Bayer outlining conditions for submitting additional postmarket information to the agency about Essure. The letter applies to reportable adverse events Bayer is or becomes aware of from social media data received in relation to litigation.
Read more: FDA Provides Updates on Adverse Event Reports and Postmarket Activities Associated with Essure